Oncotarget

Research Papers:

Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors

Zhaoxu Li, Junzhe Zhang, Jicun Tang and Ruiying Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:84388-84397. https://doi.org/10.18632/oncotarget.12756

Metrics: PDF 1680 views  |   HTML 1746 views  |   ?  


Abstract

Zhaoxu Li1, Junzhe Zhang1, Jicun Tang1, Ruiying Wang1

1Department of Orthopaedics, Affiliated Hospital, Guilin Medical University, Guilin, Guangxi, China

Correspondence to:

Ruiying Wang, email: rywang@glmc.edu.cn

Keywords: osteosarcoma, tripterine, TNF-related apoptosis-inducing ligand, immunotherapy

Received: January 17, 2016     Accepted: October 01, 2016     Published: October 19, 2016

ABSTRACT

γδ T cells has been shown to exhibit profound antitumor effects in a broad range of tumor entities, including OS. However, resistance to γδ T cells is a serious problem in the management of OS. This study investigates the impact of celastrol on the expression of death receptors 4/5 (DR4/5) on OS cell lines (HOS, U2OS) and cancer cell lysis by γδ T cells. The results showed that celastrol increased transcription of DR4/5 in HOS and U2OS, leading to increased cell surface, and total DR4/5 protein expression. Celastrol sensitizes OS cell lines or autologous OS cells to healthy donors-derived or OS patient-derived γδ T cell cytotoxicity in vitro. The induction of DR4/5 molecules increased lysis of HOS and U2OS by γδ T cells which was abolished by addition of a blocking TRAIL antibody. Importantly, the cytotoxic activity of γδ T cells was unaltered by small-dose celastrol. Taken together, our data show that celastrol up-regulated DR4/5 on OS cells to be responsible for intercellular TRAIL/APO-2L crosslink that confers increased cancer cell lysis by γδ T cells. These results suggest the clinical evaluation of celastrol in OS, especially in combination with immunotherapy approaches employing adoptive γδ T cell transfer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12756